THREE DECADES STRONG THREE DECADES STRONG Building Healthy Partnerships DRIVING SUSTAINABLE ECONOMIES

Transcription

1 THREE DECADES STRONG THREE DECADES STRONG Building Healthy Partnerships 1 DRIVING SUSTAINABLE ECONOMIES 2016

2 table of contents HCP OVERVIEW PORTFOLIO OVERVIEW CAPITAL STRUCTURE 2 OUR LEADERSHIP

3 HCP s veteran leadership Lauralee Martin President & CEO (2/39)* Troy McHenry General Counsel (6/19) Tim Schoen Chief Financial Officer (10/21) Justin Hutchens CIO Sr. Housing & Care (1/22) Business Leaders 3 Kendall Young Sr. Housing & Care (5/31) Darren Kowalske Sr. Housing & Care - AM (2/29) John Stasinos International (12/12) Tom Klaritch Medical Office (17/32) Jon Bergschneider Life Science (15/18) * Tenure (HCP/Industry) HCP OVERVIEW

4 company overview» Leadership positions in multiple segments of healthcare real estate Strong U.S. Demographics Well balanced Investment Portfolio of 1,179 properties (1) $1.9 billion Portfolio Income (2) Hospital UK 4% 4% % of U.S. Population 25% 20% 15% 10% 5% This Decade Population in Millions MOB 14% Life Science 14% $23B Investment Portfolio (1) Post-Acute/Skilled 23% Senior Housing 41% 0% % 85+ % % Population Best in class Operating Partners 4» Compound annual shareholder return of 14.9% (3) since IPO in 1985 First healthcare REIT named to the S&P 500 index 31 years of consecutive dividend growth the first REIT in the S&P 500 Dividend Aristocrats index (1) Pro forma for sale of HCR ManorCare ( HCRMC ) non-strategic assets. (2) Based on Investment Portfolio as of 12/31/15 and annualized 4Q 2015 Portfolio Income, adjusted to reflect the pro forma impact from the sale of 50 HCRMC nonstrategic assets. The percentages in the pie chart reflect each segment s income as a percentage of HCP s total Portfolio Income on a pro forma basis. (3) Through 12/31/15 and assumes re investment of dividends. HCP OVERVIEW

5 HCP the First REIT in the S&P 500 Dividend Aristocrats index 100% Annual Dividend F: 31 Years of Consecutive Dividend Increases $2.30 (1) 95% Dividend per share FAD payout ratio 90% 85% 5 80% 83% 75%» Dividend Aristocrats are S&P 500 companies that have increased dividends every year for at least 25 consecutive years» Only 10% of S&P 500 companies are in this index (1) Estimated full-year 2016 dividend based on current quarterly dividend of $0.575 per share paid on 2/23/16. HCP OVERVIEW

6 2015 highlights» Completed $2.1 billion of accretive investments focused on private pay: $1.1 billion in senior housing, led by the $847 million acquisition of Chartwell s portfolio $700 million expansion in our life science and MOB office platform, including a $225 million institutional joint venture with Morgan Stanley owning an on-campus MOB portfolio, and $177 million class A life science development of The Cove Phase I $278 million increase in our international investments, expanding our UK care home portfolio» Generated $3 billion from financing and capital recycling activities, including $2.3 billion of debt at a blended rate of 3.5% (addressed 36% of 2016 debt maturities) 6» Selling 50 HCRMC non-strategic assets for $350+ million, exceeding the high-end of our initial expectations (80% received to date)» Executed 3.2 million sq. ft. of leasing in our life science and MOB portfolios and achieved the 6 th consecutive quarterly all-time high life science occupancy of 98.2%, a 300 basis point improvement over the prior year HCP OVERVIEW

7 2016 outlook» Limited lease rollover totaling only 6%» Income from HCRMC investments will be recognized on a cash basis, eliminating $150 million of non-cash income (no impact to FAD or cash same-store reporting)» Focused on capital recycling with $450 million asset sales already under contract» Addressed 36% of 2016 debt maturities early by completing $600 million bond deal in December 2015» Remaining debt maturities of $900 million in 2016 (8% of total indebtedness)» $1.6 billion of availability under $2.0 billion revolver as of December 31, 2015» Commenced $185 million development of The Cove Phase II, in response to Phase I leasing success (half committed) and continued strong demand from life science users in South San Francisco 7 HCP OVERVIEW

8 HCP s opportunistic & disciplined capital allocation By Sector By Investment Type Senior Housing 46% $4B Accretive Acquisitions UK 26% RIDEA JV 40% Triple-net Leased 33% 7.3% Blended Going-in Cash Yield Debt Investment 18% 8 1% Post-Acute/ Skilled 8% Life Science MOB 19% 9% Development Investment pipeline focused on private pay assets HCP OVERVIEW

9 Continuing to grow and expand with Best-in-Class partners Senior Housing and Care MOB/Hospital Systems 9 Academic Institutions Life Science and Venture Capital HCP OVERVIEW

10 HCR ManorCare update Background» Second half 2015 performance declined due to ongoing, industry-wide change in reimbursement models» 2016 forecast: $505M $555M EBITDAR sensitivity range 1.06x 1.16x Projected FCC» $125M cash on hand at year-end Fixed Charge Coverage H'15 2H'15 Weakness in core SNF performance Disruption from asset sales and transitions (32 assets closed in Q4/Q1) 10» Continue reducing HCRMC concentration» Improve credit quality of HCRMC Our Highest Priorities» Ensure HCRMC s high-quality care and service delivery continues HCRMC Concentration Continue reducing Exited 50 non-strategic assets 34% Rent reduction 24% Growing private pay and operating business in other sectors Asset sales Rent reduction Several others HCRMC concentration PORTFOLIO OVERVIEW

11 Brookdale portfolio update 50% in Triple-Net Leases (12.5% of overall portfolio - $240M Cash NOI) 50% in Operating Business (RIDEA) (12.5% of overall portfolio - $240M Cash NOI)» Blended rent coverage of 1.03x» All leases guaranteed by Brookdale Corporate FCC of 1.4x (1)» Portfolio is comprised of multiple pools with staggered lease maturities» No direct credit exposure» We expect stable and growing cash NOI performance despite industry headwinds from new supply and wage pressures Only 21% of HCP s RIDEA NOI (2.7% of total Company NOI) is subject to new supply (within 5-mile radius of new construction) 3.0%-4.0% same store growth in » Annual maturities do not exceed 5% until 2023, and remain below 10% through 2027» Strong JV alignment (10% to 51% BKD ownership) CapEx investments to maintain competitive position» Diversified care mix across healthcare spectrum: SNF 3% MC 6% CCRC 32% AL 30% IL 29% (1) Source: Brookdale Q Supplemental. Adjusted for 5% management fee and capital $350/unit. PORTFOLIO OVERVIEW

12 Capital Allocation Strategy: Operating Business Private Pay Sources Two Years Ago Current Aspirational Operating Businesses 30% 40% > 50% Medical Office 13% 14% Life Science 14% 14% RIDEA Senior Housing 3% 13% Triple Net Leases 70% 60% < 50% Private Pay Sources 69% 76% > 80% 12 Expanding Portfolio in Growing, Well-Located MSAs (1) Percent Located in Top Markets 100% 80% 60% 40% 20% 0% Top 3 Markets: 95% 66% 77% 74% 74% 62% 62% 47% HCP Life LFE Science UK MOB HSP SH NNN RIDEA SNF S.F. S.F. Manchester Dallas Dallas D.C. Houston Chicago Dallas San Diego London Houston L.A. NYC Denver PHL Houston San Jose Leeds Nashville ATL PHL Chicago Detroit (1) Reflects HCP s current portfolio based on NIC-defined Top 31 MSAs for U.S. assets and HCP-defined regions for UK assets. PORTFOLIO OVERVIEW

13 $1.9 billion of Diversified Portfolio Income (1) Senior Housing 41% Post-Acute/SNF 23% 486 (2) properties across 43 states $9.8B investments Eleven development projects totaling over $500M stabilized real estate value Largest partner is Brookdale Senior Living, the pre-eminent senior housing operator in the U.S. 266 (2) properties across 29 states $4.3B investments Largest operator is HCR ManorCare, a leading provider of post-acute care Life Science 14% Medical Office 14% Hospital 4% 122 properties comprising 7.8M sq. ft. $4.0B investments High quality tenant base including Amgen, Takeda, Google and LinkedIn Largest life science portfolio and development pipeline on the U.S. West Coast Strong occupancy at an all-time high of 98.2% 228 properties across 28 states comprising 17.2M sq. ft. $3.6B investments 79% located on-campus; 95% affiliated with 200+ healthcare systems Strong occupancy of 91.9% New $225M institutional JV with Morgan Stanley on our Memorial Hermann portfolio acquired in June properties across 10 states $0.6B investments Quality operators including HCA and Hoag Memorial 13 International 4% $1 billion investment portfolio (45% real estate, 55% debt investments) $0.4B invested through sale-leasebacks in 61 care homes (1) Based on Investment Portfolio as of 12/31/15 and annualized 4Q 2015 Portfolio income, adjusted to reflect the pro forma impact from the sale of 50 HCRMC non-strategic assets. (2) Pro forma for the sale of HCRMC non-strategic assets. PORTFOLIO OVERVIEW

14 SAME-STORE GROWTH from diversified portfolio Averaging +3.3% (1) HCP S OVERALL SAME-STORE CASH NOI GROWTH % 4.0% 4.2% 3.1% 3.3% SAME- STORE GROWTH BY SEGMENT % 3.7% Excluding HCR ManorCare Hospital 9.9% Senior Housing 6.6% Life Science 7.0% Senior Housing 5.1% Senior Housing 3.6% Life Science 6.5% 14 Senior Housing 8.6% Hospital 4.6% Post-acute/Skilled 3.7% Hospital 3.7% Post-acute/Skilled 3.5% Senior Housing 3.7% Medical Office 2.7% Medical Office 2.8% Hospital 3.6% Post-acute/Skilled 3.5% Life Science 3.4% Hospital 2.8% Post-acute/Skilled 1.4% Post-acute/Skilled 2.6% Senior Housing 3.5% Medical Office 2.3% Hospital 3.1% Medical Office 2.1% Life Science 0.5% Life Science 1.1% Medical Office 2.7% Life Science (1.6%) Medical Office 2.0% Post-acute/Skilled (7.1%) (1) Represents HCP s average same-store Cash NOI growth from , inclusive of the 2015 HCRMC lease amendment. PORTFOLIO OVERVIEW

15 Expanding UK investment platform» $1 billion investment portfolio (1) $0.4 billion invested through sale-leasebacks in 61 care homes; long-term NNN leases with EBITDARM coverages of 1.6x and cash yields of 7.3% $0.6 billion debt investments» Key relationships with HC-One (third largest operator) and Maria Mallaband (top ten operator focused on private pay care homes) 15 Total UK Portfolio by Investment Type (1) UK Real Estate Portfolio by Operator (1) Debt Investments $0.6B 56% Real Estate $0.4B 44% HC-One $250M 60% Maria Mallaband $170M 40% (1) As of 12/31/2015. PORTFOLIO OVERVIEW

16 developments provide attractive risk adjusted return Location Affiliation Estimated Completion Date Capacity Investment Through 12/31/15 (in millions) Estimated Total Investment (in millions) Development Robin Run Village (CCRC JV) Indianapolis, IN Brookdale 1Q Units $5 $6 Pearland II (MOB) Pearland, TX Memorial Hermann 1Q k Sq. Ft. $14 $19 Deer Park (IL/AL) Deer Park, IL Formation Capital 1Q Units $41 $48 Sky Ridge (MOB) Lone Tree, CO HCA 1Q k Sq. Ft. $23 $29 Vintage Park JV (IL) Houston, TX Formation Capital 2Q Units $10 $24 Cypress (MOB) The Cove - Phase I (LSE) Cypress TX S. San Francisco, CA Memorial Hermann CytomX, Denali 2Q k Sq. Ft. $20 $36 3Q k Sq. Ft. $93 $ Oakmont Village JV (AL) Santa Rosa, CA MBK (Mitsui) 1Q Units $2 $12 Woodlands Plaza 4 (MOB) The Woodlands, TX Memorial Hermann 2Q k Sq. Ft. $-- $37 The Cove - Phase II (LSE) S. San Francisco, CA TBD 3Q k Sq. Ft. $21 $185 Redevelopment Folsom (MOB) Sacramento, CA UC Davis (Tenant) 2Q k Sq. Ft. $60 $62 Bayfront (1) (MOB) St. Petersburg, FL CHS 2Q k Sq. Ft. $14 $22 Avg./Total $303 $664» Developments represent an attractive risk adjusted return in an environment where acquisition pricing has become aggressive» Life science fundamentals have been strong, particularly in the Bay Area, driven in part by biotech companies access to capital» Our phased development projects focus on class A real estate in strong markets with proven developers and operators, with appropriate levels of pre-leasing (1) Represents a portion of the facility. PORTFOLIO OVERVIEW

17 HCP FAD and Dividend growth 3%+ average same-store Cash NOI growth (1) 70% expansion of Investment Portfolio Balance sheet upgrade Baa3 BBB Baa1 BBB+ 7.2% FAD/Share CAGR FAD/share Dividend/share $2.54 $2.57 $2.72 Dividend Payout Ratio FAD 17 FAD $1.92 $2.16 $1.92 $2.23 $2.00 $2.10 $2.18 $ % IN 2010 $ % IN $20M FAD in excess of dividends $200M (1) Represents HCP s average same-store Cash NOI growth from , inclusive of the 2015 HCRMC lease amendment. PORTFOLIO OVERVIEW

18 committed to a Solid Balance Sheet» Target a balanced portfolio between longer-term escalating NNN leases and operating businesses with shorter-term leases in our Office and RIDEA platforms Limited RIDEA exposure (~13% Portfolio Income) compared to HCP s peers Long-term leases financed with long-term fixed rate debt» Conservative capital structure New acquisitions underwritten at 40% (debt) / 60% (equity) capital structure 18 Minimal floating interest rate exposure Standard REIT covenant package» Strong liquidity and proven market access $2.0 billion multi-currency revolver Issued $600 million of 7-year unsecured debt in December 2015 at a rate of 4.0% Issued $750 million of 10-year unsecured debt in May 2015 at a rate of 4.0% Issued $600 million of 10-year unsecured debt in January 2015 at a rate of 3.4% CAPITAL STRUCTURE

19 strong BALANCE SHEET WITH laddered DEBT MATURITIES (1)(2) ($ millions) $1,600 Refinancing tailwinds over next several years $1,395 Unsecured Term Loan Secured Debt (w/ pro rata JV) Senior Unsecured Notes $1,369 $1,200 $1,222 $1,151 $800 $883 $778 $831 $916 $ $635 $400 $350 $ Thereafter 5.5% 5.9% 6.7% 3.1% 2.8% 5.5% 3.9% 4.4% 4.1% 3.9% 6.6% (1) Debt maturity schedule as of December 31, Pro forma to reflect prefunding certain 2016 debt maturities in December (2) Excludes revolver and $287 million of other debt comprised of life care bonds, entrance fee liabilities and demand notes to the CCRC JV. CAPITAL STRUCTURE

20 maintaining Ample Near-Term Liquidity ($ in millions) $2,400 ~$2 Billion Immediate Liquidity from Revolver, Asset Sales & Retained Cash $0.9 Billion Remaining Maturities $2,000 $1,600 $1,200 Senior Unsecured Notes Secured Debt GBP Term Loan 20 $800 $400 $167 $ $24 $9 $202 $35 $400 $25 Apr May Jun Jul Aug Sep Oct Nov Dec CAPITAL STRUCTURE

21 well-managed debt profile (1) Weighted Average Interest Rate Weighted Average Maturity 6.25% % 5.75% 5.50% 5.25% 5.00% 4.75% % % 95% Percentage of Fixed Rate Debt» Reduced weighted average interest rate by 160 bps since %» Increased weighted average maturity to 5.6 years 85%» Less than 5% of debt is floating rate 80% (1) As of December 31, Pro forma to reflect prefunding certain 2016 debt maturities in December CAPITAL STRUCTURE

22 WHAT MAKES HCP compelling WE ARE: A disciplined and creative capital allocator A capital partner with strong balance sheet and liquidity An S&P 500 Dividend Aristocrat A global sustainability leader WE HAVE: 300+ healthcare relationships Multiple avenues to achieve growth Deep industry expertise across healthcare sectors A uniquely diversified portfolio: robust Life Science and sector leading CCRC Platforms 22 WE GROW: the value of our cash flows from our portfolio, via long-term ownership in healthcare real estate that is strategic to our operating partners OUR LEADERSHIP

23 HCP is a leader in Sustainability CDP Investor Survey Named to Climate Disclosure Leadership Index for 2 of the past 3 years Global Real Estate Sustainability Benchmark Survey Named GRESB Global Healthcare Sector Leader for 3 of the past 4 years NAREIT Leader in the Light Survey Awarded NAREIT Healthcare Leader in the Light for 3 of the past 4 years 23 Dow Jones Sustainability Index Assessment Named to DJS Index North America for 3 rd consecutive year Named to DJS World Index for the 1 st time (2015) FTSE4Good Index Series Named to the FTSE4Good Index for 4 th consecutive year Global Reporting Initiative Sustainability Report Published 1 st Combined Annual + Sustainability Report 4 th year to publish in accordance with the GRI G4 framework OUR LEADERSHIP

24 green BUSINESS This presentation is being presented solely for your information, is subject to change and speaks only as of the date hereof. This presentation and comments made by management do not constitute an offer to sell or the solicitation of an offer to buy any securities of HCP or any investment interest in any business ventures of HCP. This presentation is not complete and is only a summary of the more detailed information included elsewhere, including in HCP s Securities and Exchange Commission filings. No representation or warranty, expressed or implied is made and no reliance should be placed on the accuracy, fairness or completeness of the information presented. HCP, its affiliates, advisers and representatives accept no liability whatsoever for any losses arising from any information contained in this presentation. FORWARD-LOOKING STATEMENTS The statements in this presentation, as well as statements made by management, which are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and HCP intends such forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of These statements include, among other things, statements regarding FFO, FAD, income, credit metrics and other financial projections and assumptions; financing expectations; future business strategies, including but not limited to HCP s development pipeline; HCRMC financial projections and asset sales proceeds; and dividends. These statements are made as of the date hereof, are not guarantees of future performance and are subject to known and unknown risks, uncertainties, assumptions and other factors many of which are out of HCP s control and difficult to forecast that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to: HCRMC s ability to meet its contractual obligations under the HCRMC lease amendment and risks related to the impact of the U.S. Department of Justice lawsuit against HCRMC, including the possibility of larger than expected litigation costs, adverse results and related developments; HCP s reliance on a concentration of a small number of tenants and operators for a significant portion of its revenues; the financial weakness of tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings; the ability of HCP s tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and to generate sufficient income to make rent and loan payments to HCP; competition for tenants and operators; competition for skilled management, nurses and other trained personnel; availability of suitable properties to acquire at favorable prices and the competition for the acquisition and financing of those properties; the ability of HCP s own tenants and operators to maintain costs and to compete for skilled management and nurses; HCP s ability to negotiate the same or better terms with new tenants or operators if existing leases are not renewed or HCP exercises its right to replace an existing tenant or operator upon default; the risks associated with HCP s investments in joint ventures and unconsolidated entities; HCP s ability to achieve the benefits of investments within expected time frames or at all, or within expected cost projections; the potential impact on HCP and its tenants, operators and borrowers from current and future litigation matters; the effect on healthcare providers of legislation addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements; the availability and cost of capital as impacted by interest rates, changes in our credit ratings, and the value of HCP s common stock; changes in federal, state or local laws and regulations; volatility or uncertainty in the capital markets; changes in global, national and local economic conditions, and currency exchange rates HCP s ability to manage its indebtedness level and changes in the terms of such indebtedness; HCP s ability to maintain its qualification as a real estate investment trust; and other risks and uncertainties described from time to time in HCP s Securities and Exchange Commission filings, including its 2015 Annual Report on Form 10-K. HCP assumes no, and hereby disclaims any, obligation to update any of the foregoing or any other forward-looking statements as a result of new information or new or future developments, except as otherwise required by law. NON-GAAP FINANCIAL MEASURES This presentation contains certain supplemental non-gaap financial measures. While HCP believes that non-gaap financial measures are helpful in evaluating its operating performance, the use of non-gaap financial measures in this presentation should not be considered in isolation from, or as an alternative for, a measure of financial or operating performance as defined by GAAP. You are cautioned that there are inherent limitations associated with the use of each of these supplemental non-gaap financial measures as an analytical tool. Additionally, HCP s computation of non-gaap financial measures may not be comparable to those reported by other REITs. Reconciliations of the non GAAP financial measures to the most directly comparable GAAP financial measures can be found in HCP s supplemental information packages and earnings releases, which are available on its website at in the Presentations section of the Investor Relations tab. 24